Physician profile
Prashant Verma
NPI 1972787638
$61,740.59
in general payments reported to CMS, 2019-2025
42 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,429 · 2020: $2,051 · 2021: $3,182 · 2022: $6,464 · 2023: $23K · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $11K · Consulting Fee: $8,759 · Travel and Lodging: $3,512 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,725.00 |
| Food and Beverage | $11,497.24 |
| Consulting Fee | $8,759.42 |
| Travel and Lodging | $3,512.05 |
| Education | $121.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $31,116.73 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $8,307.80 | 2019-2025 | Hizentra, Andembry |
| Astrazeneca Pharmaceuticals Lp | $5,154.79 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $3,102.33 | 2019-2025 | |
| Alk-Abello, INC | $1,774.17 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Amgen INC. | $1,709.50 | 2021-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $1,683.39 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $1,666.78 | 2020-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $1,226.79 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $749.29 | 2020-2025 | Takhzyro, Cuvitru |
| Bio Products Laboratory USA, INC. | $524.12 | 2019-2023 | Gammaplex, Coagadex |
| Pfizer INC. | $479.71 | 2019-2025 | |
| Blueprint Medicines Corporation | $418.94 | 2022-2025 | Ayvakit |
| Octapharma USA, INC. | $397.17 | 2019-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Shire North American Group INC | $376.48 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.